Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-17T17:15:15.039Z Has data issue: false hasContentIssue false
  • English
  • Français

A Non-Profit Approach to Address Foreign Dependence of Generic Drugs

Published online by Cambridge University Press:  21 April 2021

Dan Liljenquist ,
Ge Bai ,
Ameet Sarpatwari  and
Gerard F. Anderson
Get access Rights & Permissions [Opens in a new window]

Abstract

The COVID-19 pandemic has revealed the vulnerability of the US generic drug supply chain to foreign production. Many policies have been proposed to mitigate this vulnerability. In this article, we argue that nonprofit drug manufacturers have the potential to make important contributions.

Keywords

Generic DrugPrescription Drug ManufacturingForeign DependenceNon-profitDrug Supply Chain
Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 49 , Issue 1: Public Sector and Non-Profit Contributions to Drug Development: Historical Scope, Opportunities, and Challenges , Spring 2021 , pp. 30 - 33
Copyright
© 2021 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

See, for example, Alexander, G.C. and Qato, D. M., “Ensuring Access to Medications in the US during the COVID-19 Pandemic”, JAMA 324, no. 1 (2020): 31–32; R. Gibson, “Testimony before the Senate Committee on Small Business and Entrepreneurship: The Coronavirus and America’s Small Business Supply Chain”, US Senate, March 12, 2020, available at <https://www.sbc.senate.gov/public/_cache/files/1/c/1c39a1bc-f22c-4178-951e-29b92dcb2182/3AD9C94FB267763A83913E2303A6A772.gibson-testimony.pdf> (last visited September 25,2020); C. Yap, “Pandemic Lays Bare U.S. Reliance on China for Drugs”, The Wall Street Journal, August 5, 2020, available at https://www.wsj.com/articles/how-the-u-s-ceded-control-of-drug-supplies-to-china-11596634936 (last visited September 25, 2020); K. Thomas, “First Drug Shortage Caused by Corona-virus, F.D.A. Says. But It Won’t Disclose What Drug or Where It’s Made”, The New York Times, February 28, 2020, available at <https://www.nytimes.com/2020/02/28/health/drug-coronavirus-shortage.html>- (last visited September 25, 2020); S. Lupkin, “How Coronavirus Is Affecting the U.S. Pharmaceutical Supply”, NPR, March 12, 2020, available at <https://www.npr.org/sections/health-shots/2020/03/12/814623335/how-coronavirus-is-affecting-the-u-s-pharmaceutical-supply> (last visited September 25, 2020); G.F. Anderson, “Testimony before the Senate Committee on Small Business and Entrepre-neurship: the Coronavirus and America’s Small Business Supply Chain”, US Senate, March 12, 2020, available at <https://www.sbc.senate.gov/public/_cache/files/c/8/c8364a30-8bc9-4f4f-bed7-825410df455e/0CCE5A7EEB15AF18E0FA4E1510082FE9.anderson-testimony.pdf> (last visited September 25,2020).CrossRefGoogle ScholarPubMed
See, for example, Alexander, G.C. and Qato, D. M., “Ensuring Access to Medications in the US during the COVID-19 Pandemic”, JAMA 324, no. 1 (2020): 31–32; T. Dai, G. Bai, and G.F. Anderson, “PPE Supply Chain Needs Data Transparency and Stress Testing”, Journal of General Internal Medicine 35, no. 9 (2020): 2748-2749.CrossRefGoogle ScholarPubMed
See, for example, Yap, C., “Pandemic Lays Bare U.S. Reliance on China for Drugs”, The Wall Street Journal, August 5, 2020, available at <https://www.wsj.com/articles/how-the-u-s-ceded-control-of-drug-supplies-to-china-11596634936> (last visited September 25, 2020); K. Thomas, “First Drug Shortage Caused by Coronavirus, F.D.A. Says. But It Won’t Disclose What Drug or Where It’s Made”, The New York Times, February 28, 2020, available at <https://www.nytimes.com/2020/02/28/health/drug-coronavirus-shortage.html> (last visited September 25, 2020); S. Lupkin, “How Cora-onavirus Is Affecting the U.S. Pharmaceutical Supply”, NPR, March 12, 2020, available at <https://www.npr.org/sections/health-shots/2020/03/12/814623335/how-coronavirus-is-affecting-the-u-s-pharmaceutical-supply> (last visited September 25, 2020); B. Freeman, “Drug Shortage Loom Due to Coronavirus”, Newsmax, February 23, 2020, available at <https://www.newsmax.com/newsfront/coronavirus-drugs-china/2020/02/23/id/955350/> (last visited September 25, 2020); R. Gibson, supra note 1.+(last+visited+September+25,+2020);+K.+Thomas,+“First+Drug+Shortage+Caused+by+Coronavirus,+F.D.A.+Says.+But+It+Won’t+Disclose+What+Drug+or+Where+It’s+Made”,+The+New+York+Times,+February+28,+2020,+available+at++(last+visited+September+25,+2020);+S.+Lupkin,+“How+Cora-onavirus+Is+Affecting+the+U.S.+Pharmaceutical+Supply”,+NPR,+March+12,+2020,+available+at++(last+visited+September+25,+2020);+B.+Freeman,+“Drug+Shortage+Loom+Due+to+Coronavirus”,+Newsmax,+February+23,+2020,+available+at++(last+visited+September+25,+2020);+R.+Gibson,+supra+note+1.>Google Scholar
Gibson, R., supra note 1.Google Scholar
Yap, C., supra note 1.Google Scholar
Gibson, R., supra note 1.Google Scholar
Gibson, R., supra note 1.Google Scholar
The White House, “Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States”, August 6, 2020, available at <https://www.whitehouse.gov/presidential-actions/executive-order-ensuring-essential-medicines-medical-counter-measures-critical-inputs-made-united-states/> (last visitedSeptember 25, 2020).+(last+visitedSeptember+25,+2020).>Google Scholar
Liljenquist, D., Bai, G., and Anderson, G.F., “Addressing Generic-Drug Market Failures — the Case for Establishing a Nonprofit Manufacturer”, New England Journal of Medicine 378, no. 20 (2018): 1857–1859.CrossRefGoogle ScholarPubMed
California Legislature, SB-952 Health Care: Prescription Drugs, September 28, 2020, available at <https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201920200SB852> (last visited October 10, 2020).+(last+visited+October+10,+2020).>Google Scholar
Id.Google Scholar